Abstract

Charles River Laboratories is scheduled to report fiscal first‑quarter 2026 results on May 7, 2026 Pre-Market; consensus anticipates modest year-over-year revenue growth with softer earnings per share as mix shifts and transaction timing shape margins and operating leverage.

Market Forecast

Consensus points to fiscal Q1 2026 revenue of 977.49 million US dollars, up 3.77% year over year, with adjusted EPS around 1.94, a 6.55% decline year over year; modeled EBIT is 152.00 million US dollars, implying a 10.68% annual drop on margin pressure from revenue mix and normalizing utilization. The company did not disclose a specific Q1 revenue target in its prior report, focusing instead on 2026 full-year guidance and portfolio actions; in this context, the market’s expectations anchor to a modest top-line increase and lower per-share earnings as the business transitions its portfolio.

Management flagged improved net bookings in Discovery and Safety Assessment (DSA) exiting fiscal 2025 and is pursuing efficiency measures and portfolio pruning to simplify operations and refocus capital; near-term margins depend on the cadence of project starts, the timing of divestitures, and cost actions taking hold. Within the portfolio, Discovery and Safety Assessment appears the most consequential for near-term upside given stronger order trends in Q4 FY2025 and supply-chain initiatives; in the last reported quarter, DSA revenue was 591.60 million US dollars (-2.00% year over year), while Research Models and Services delivered 206.30 million US dollars (+1.00%) and Manufacturing Solutions reached 196.40 million US dollars (+0.70%).

Last Quarter Review

In Q4 FY2025, Charles River Laboratories reported revenue of 994.23 million US dollars (-0.83% year over year), a gross profit margin of 33.08%, a GAAP net loss attributable to common shareholders of approximately 277.00 million US dollars with a net profit margin of -27.82%, and adjusted EPS of 2.39 (-10.15% year over year). A key driver of the GAAP loss was non-cash charges, including intangible and goodwill impairments, while underlying operating performance on a non-GAAP basis remained profitable and consistent with the company’s seasonal profile.

A notable business highlight was stronger net bookings in Discovery and Safety Assessment as the quarter closed, supporting an improving conversion pipeline into 2026. By segment in Q4 FY2025, Discovery and Safety Assessment revenue was 591.60 million US dollars (-2.00% year over year), Research Models and Services contributed 206.30 million US dollars (+1.00%), and Manufacturing Solutions posted 196.40 million US dollars (+0.70%), reflecting mixed demand across service lines but constructive order trends to start the new fiscal year.

Current Quarter Outlook (with major analytical insights)

Discovery and Safety Assessment: bookings momentum and supply-chain actions set the tone

Discovery and Safety Assessment (DSA) is positioned to be the principal swing factor for fiscal Q1 2026 given Q4 order strength and project start timing. The consensus revenue trajectory for the quarter implies that recently signed work, if converted on schedule, should support a sequentially stable workload and mix, even though year-over-year comparisons remain uneven. Margin sensitivity in DSA this quarter will likely hinge on utilization of high-fixed infrastructure and project mix, with incremental operating leverage materializing if booked studies transition to in-life phases earlier in the quarter. Portfolio and supply-chain steps taken since January are also relevant. The announced agreement to acquire K.F. (Cambodia) Ltd., a key nonhuman primate source, aims to secure critical inputs and reduce procurement costs over time; while the financial consolidation is not expected to transform Q1 results, better supply assurance can mitigate schedule risk and pricing volatility as the year progresses. Management has described cost and efficiency actions to streamline workflows; their early-quarter contribution should be modest, with larger benefits accruing as throughput normalizes, leaving Q1 DSA margins primarily a function of study starts and idle-time absorption.

Research Models and Services: price and volume discipline while managing normalization

Research Models and Services (RMS) exited 2025 with a slight year-over-year revenue increase, and it could underpin base growth in Q1 2026 as price realization and steady demand for core models provide stability. The consensus EPS step down relative to last year suggests that even if RMS grows modestly, its mix contribution to consolidated gross margin may be diluted by higher-weight DSA workflows still ramping toward fuller utilization. RMS operating margin in the quarter will depend on throughput and logistics efficiency; tighter cost controls and standardization initiatives should offset part of wage and logistics inflation. In addition, inventory and cycle management remain focal points. Execution risks are relatively contained compared with services tied to complex study designs, yet consolidated earnings are sensitive to RMS’s ability to maintain consistent fulfillment and avoid expedited costs. All else equal, RMS can act as a buffer in a quarter when the services-heavy lines adjust to the new fiscal year cadence, but it is unlikely to drive a material EPS outperformance without a corresponding margin lift in DSA.

Manufacturing Solutions: steady contribution amid portfolio changes

Manufacturing Solutions delivered slight year-over-year growth in Q4 FY2025 and should continue to contribute stable revenue in Q1, although margin trajectories could vary with product mix and volume allocations. The pending divestitures—specifically the sale of certain discovery services sites to IQVIA and the separation of CDMO and Cell Solutions businesses—are structured to close in the second quarter; therefore, their direct revenue and EPS impact is expected to be limited in Q1. However, transition costs and implementation activities can increase short-term expense intensity, modestly weighing on first-quarter margins. Operationally, Manufacturing Solutions benefits when production schedules run predictably and when demand mix supports favorable absorption. With consensus modeling a year-over-year EBIT decline for the quarter, investors should watch for commentary on backlog and order visibility within this line, as even small variations in throughput or product mix can influence consolidated gross margin and EBIT flow-through.

Key factors likely to drive the stock this quarter

- Conversion of DSA bookings into revenue and the quality of the in-quarter start pipeline. If the stronger Q4 bookings convert at pace, the revenue run-rate can align with or exceed the consensus path, supporting improved fixed-cost absorption and narrowing the EPS gap implied by forecasts. If starts slip to later in the year, operating leverage could disappoint in Q1 even if the backlog remains healthy. - Early impact from portfolio optimization and cost measures. The company is pruning non-core assets and focusing investment where returns are clearest. In Q1, investors will likely focus on evidence of expense discipline—SG&A and project delivery costs—as a leading indicator that the full-year margin plan is on track, even before divestitures close. - Cash flow outlook and capital allocation signals. With full-year 2026 guidance updated to reflect divestitures—lower reported revenue expectations but slightly higher adjusted EPS range—commentary on in-year cash conversion, working capital timing, and the pace of reinvestment can influence sentiment. Indications that supply chain steps (including the K.F. (Cambodia) transaction) are improving schedule reliability may bolster confidence in the trajectory for the second half. - Pricing and mix commentary. Given consensus sees revenue up but EPS down year over year in Q1, any qualitative or quantitative color around pricing discipline and mix within DSA and RMS will be central to understanding the near-term EPS bridge. Even moderate mix shifts toward more complex work can add revenue but temporarily dilute margins until utilization normalizes.

Analyst Opinions

Across the January 1, 2026 to April 30, 2026 window, the balance of published views skews bullish for the near term, with two clearly positive stances versus zero bearish calls, while several neutrals emphasize execution and portfolio transition. The majority view centers on a constructive setup into 2026 as order trends improve and portfolio actions simplify the business model, even if the first quarter reflects transitional margin dynamics.

RBC Capital Markets initiated coverage with an Outperform rating and a 215 US dollars price target in mid-April, highlighting an emerging upswing in client research activity and the potential for acceleration as the year progresses. Their thesis emphasizes that better order inflow, if sustained, should translate into higher utilization and gradual margin rebuilding, especially within Discovery and Safety Assessment. In the quarter at hand, RBC’s stance implies that the critical indicators are bookings conversion and commentary on cycle time improvements, rather than an immediate step-change in profitability.

Baird maintained an Outperform rating while raising its price target to 200 US dollars in early April, framing the quarter as a checkpoint on execution: demonstrating that backlog is converting in line with plans, that pricing remains intact, and that cost actions are visible in the run-rate. Baird’s constructive tone suggests that a modest top-line beat would be less important than management confirming the cadence of project starts, the stability of the revenue mix, and the anticipated timing of portfolio changes and their limited Q1 impact. Under this view, softer EPS in Q1 would be consistent with a typical lag between revenue normalization and margin recovery, provided the qualitative signals on bookings and operations are favorable.

Taken together, the majority opinion expects fiscal Q1 2026 results to align with a transition quarter: revenue up around 3.77% year over year, with adjusted EPS down approximately 6.55% and EBIT lower by roughly 10.68%, reflecting business mix and timing. The bullish case rests on confirmation that Q4’s stronger DSA bookings are turning into work on the bench, that supply chain initiatives are lowering scheduling risk, and that portfolio actions are progressing on plan—elements that, if validated on May 7, 2026 Pre-Market, could support higher confidence in the rest-of-year earnings trajectory even if Q1 margins remain compressed.